NEW YORK – The UK's National Institute for Health and Care Excellence on Tuesday recommended Bristol Myers Squibb's immunotherapy combination Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line ...

The firms will explore molecular mechanisms and patient responses in cancer to inform development of new therapies.

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.

This small branch played a big role in advancing evidence-based genetic testing, and its loss diminishes US leadership in ...

Trodelvy combo improved progression-free survival in patients with PD-L1-positive tumors compared to Keytruda-chemo.

Ono has an exclusive option to discover, develop, and commercialize drug candidates based on RNA-editing drug sequences designed by Jorna.

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.

NEW YORK – Cardiff Oncology on Tuesday said it has completed enrolling patients with advanced RAS-mutated colorectal cancer in a Phase II trial testing the activity of its PLK1 inhibitor onvansertib ...

A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.

The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.

Databricks will contribute data engineering and AI expertise to support the development of Tevogen's PredicTcell technology.